The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the Chief Executive Officer of hVIVO, to discuss these issues. Mo has over 25 years of experience in clinical research and the contract research organisation (CRO) sector, which provides him with a deep understanding of the unique hurdles these businesses encounter.
Mo Khan began by sharing his professional journey, which started in 1996. He has worked in various CROs, including some of the industry’s largest. A notable period of his career was at Pharm-Olam, a company he helped grow from a small CRO to a mid-sized global entity. This growth culminated in the company’s sale to a private equity firm. Following a brief hiatus, Mo joined Open Orphan as a non-executive director in October 2021, later assuming the CEO position in February 2022. Shortly after, the company was rebranded to hVIVO, and Mo has led the company since then.
The discussion touched upon the complexities that high-growth firms face, especially in regions like the UK, where regulations and compliance present significant challenges. For further insights, listeners are encouraged to explore the full episode of the podcast, where Mo delves deeper into these issues and shares his perspective on the future of the life sciences sector.
The conversation highlights the intricate balance between business growth and regulatory compliance, an ongoing struggle for many companies in the life sciences field.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
